Special Issue

Topic: Ferroptosis, Cuproptosis, and Drug Resistance Research in Cancer

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 31 Jul 2024

Guest Editor(s)

Dr. Xin Chen
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.

Special Issue Introduction

Iron and copper ions are essential elements for life, but they also play a key role in tumor occurrence and development. Ferroptosis and cuproptosis, different from cell apoptosis, are newly identified modes of cell death. Ferroptosis is a form of regulated death driven by iron-dependent phospholipid peroxidation, while cuproptosis is caused by copper overload-triggered mitochondrial function disorder. Mounting evidence links ferroptosis and cuproptosis intricately to cancer initiation, growth, and metastasis. In addition, pharmacological induction of ferroptosis or cuproptosis could be a novel approach to kill specific tumors or drug-resistant tumor cells. The evolving understanding of the ferroptosis or cuproptosis ecosystem has led to the development of novel cancer therapy strategies based on ferroptosis or cuproptosis, including small molecular compounds, natural compounds, nanomedicine, PROTAC, combined medication therapy, etc. This Special Issue, titled “Ferroptosis, Cuproptosis, and Drug Resistance Research in Cancer”, aims to compile Original Articles, Reviews, Commentaries, etc., focusing on novel perspectives in the field of ferroptosis and cuproptosis in oncology, especially concerning drug resistance.

Topics include but are not limited to:
1.The role of ferroptosis or cuproptosis in tumor progression, metastasis, or drug resistance;
2.The mechanisms of ferroptosis or cuproptosis resistance in cancer;
3. The development of agents targeting ferroptosis or cuproptosis for cancer treatment or reversing drug resistance;
4. Ferroptosis- or cuproptosis-related signaling pathways in cancer drug resistance;
5. Biomarkers associated with ferroptotic or cuproptotic pathways for cancer drug resistance;
6. Crosstalk between ferroptosis and cuproptosis in cancer.

Submission Deadline

31 Jul 2024

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR231031
Submission Deadline: 31 Jul 2024
Contacts: Wendy Liu, Assistant Editor, wendy@oaeservice.com

Published Articles

Coming soon
Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us


All published articles will preserved here permanently:



All published articles will preserved here permanently: